

FOSUN PHARMA INDUSTRIAL PTE. LTD.  
(the "Company")  
(Company Registration No. 201619223W)  
(Incorporated in the Republic of Singapore)

June 20, 2024

**BSE Limited**

1<sup>st</sup> floor, Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai 400 001  
Maharashtra, India

**National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai 400 051  
Maharashtra, India

**Gland Pharma Limited**

Plot No. 11 & 84, TSIIC Phase: IV Pashamylaram (V)  
Patancheru (M), Sangareddy District  
Hyderabad 502307, Telangana, India


Sir/ Madam,

**Sub: Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 by Fosun Pharma Industrial Pte. Ltd. in respect of sale of equity shares of Gland Pharma Limited**

In compliance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended, please find enclosed the requisite disclosure.

Yours sincerely,

**For Fosun Pharma Industrial Pte. Ltd.**



---

Name: Yao Fang  
Designation: Director  
Place: Shanghai

FOSUN PHARMA INDUSTRIAL PTE. LTD.  
(the "Company")  
(Company Registration No. 201619223W)  
(Incorporated in the Republic of Singapore)

**Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended**

Name of the Target Company (TC)	Gland Pharma Limited		
Name(s) of the acquirer and <del>Persons Acting in Concert (PAC) with the acquirer</del>	Seller: Fosun Pharma Industrial Pte. Ltd.		
Whether the acquirer belongs to Promoter/ Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited National Stock Exchange of India Limited		
Details of the <del>acquisition</del> / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
<b>Before the acquisition under consideration, holding of:</b>			
a) Shares carrying voting rights	95,293,894	57.84	57.84
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	Nil	Nil	Nil
c) Voting rights (VR) otherwise than by shares	Nil	Nil	Nil
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	Nil	Nil
<b>e) Total (a+b+c+d)</b>	<b>95,293,894</b>	<b>57.84</b>	<b>57.84</b>
<b>Details of acquisition/sale</b>			
a) Shares carrying voting rights acquired/sold	9,900,000	6.01	6.01
b) VRs acquired/sold otherwise than by shares	Nil	Nil	Nil
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	Nil	Nil	Nil
d) Shares encumbered /invoked/released by the acquirer	Nil	Nil	Nil

FOSUN PHARMA INDUSTRIAL PTE. LTD.  
(the "Company")  
(Company Registration No. 201619223W)  
(Incorporated in the Republic of Singapore)


<b>e) Total (a+b+c+d)</b>	<b>9,900,000</b>	<b>6.01</b>	<b>6.01</b>
<b>After the acquisition/sale, holding of:</b>			
a) Shares carrying voting rights	85,393,894	51.83	51.83
b) Shares encumbered with the acquirer	Nil	Nil	Nil
c) VRs otherwise than by shares	Nil	Nil	Nil
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	Nil	Nil
<b>e) Total (a+b+c+d)</b>	<b>85,393,894</b>	<b>51.83</b>	<b>51.83</b>
Mode of acquisition/sale (e.g. open market/ off-market/ public issue / rights issue / preferential allotment/ inter-se transfer etc.).	Open market sale		
Date of acquisition/sale of shares/VR or date of receipt of intimation of allotment of shares, whichever is applicable	June 19, 2024		
Equity share capital/ total voting capital of the TC before the said acquisition/sale	164,751,723 equity shares of ₹1 each (as per the shareholding as on 18 June, 2024 as publicly disclosed by the TC on the portal of Ministry of Corporate Affairs of India)		
Equity share capital/ total voting capital of the TC after the said acquisition/sale	164,751,723 equity shares of ₹1 each (as per the shareholding as on 18 June, 2024 as publicly disclosed by the TC on the portal of Ministry of Corporate Affairs of India)		
Total diluted share/voting capital of the TC after the said acquisition/sale	164,751,723 equity shares of ₹1 each (as per the shareholding as on 18 June, 2024 as publicly disclosed by the TC on the portal of Ministry of Corporate Affairs of India)		

(\*) Total share capital/ voting capital to be taken as per the latest filing made by the TC with the Stock Exchanges under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, i.e., the shareholding pattern as of March 31, 2024 and the announcement of allotment of shares to employees against the exercise of share options on June 7, 2024.

(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC

FOSUN PHARMA INDUSTRIAL PTE. LTD.  
(the "Company")  
(Company Registration No. 201619223W)  
(Incorporated in the Republic of Singapore)

**For Fosun Pharma Industrial Pte. Ltd.**

A handwritten signature in black ink, appearing to be the Chinese characters '姚芳' (Yao Fang), written over a horizontal line.

Name: Yao Fang

Designation: Director

Place: Shanghai